Targets › TAG72
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2028.
Open in Phaseline: the race on TAG72, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | TAG72-CAR T cells Chimeric antigen receptor T-cell therapy targeting TAG72 | TAG72 | Phase 1 | Platinum-Resistant Ovarian Carcinoma | Nov 2028 |
Platinum-Resistant Ovarian Carcinoma (1)
mixed (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.